Moss Genomics Inc. (CSE: MOSS) (“Moss” or the “Company”), a consumer genomics and gut microbiome company based in Vancouver, British Columbia, announces that the Company has granted incentive stock options to certain directors, officers and consultants to acquire 1,320,000 common shares of the Company at a price of C$0.10 per share, vesting immediately.
Vancouver, British Columbia--(Newsfile Corp. - February 27, 2023) - Moss Genomics Inc. (CSE: MOSS) (“Moss” or the “Company”), a consumer genomics and gut microbiome company based in Vancouver, British Columbia, announces that the Company has granted incentive stock options to certain directors, officers and consultants to acquire 1,320,000 common shares of the Company at a price of C$0.10 per share, vesting immediately.
Moss has created an online healthcare and technology platform integrating labs, services and products in a shared economy. Moss provides comprehensive and affordable, at-home genetic and microbiome testing paired with personalized wellness reports and offerings to promote total gut, mind and body health. The Company’s services include health reports, personalized food and nutrition recommendations, and a social media platform that allows customers to form communities based on their specific health needs. The Company’s current and anticipated products can be found in the “Shop” section of its website.
For further information concerning Moss and its business, please view the Company’s long form prospectus dated December 13, 2022 (the “Prospectus”) and CSE listing statement dated January 16, 2023 (the “Listing Statement”), as well as the Company’s website at www.mossgenomics.com. Copies of the Prospectus and Listing Statement are available on the Company’s SEDAR profile at www.sedar.com.
About Moss Genomics Inc.
Moss Genomics Inc. is an emerging consumer genomics company that offers personalized health, anti-aging and wellness offerings guided by genomic, microbiome, and epigenome data. The Company intends to eliminate barriers in healthcare by offering easy-access, at-home, affordable testing paired with easy-to-understand actionable results.
For further information, please contact:
Karl Cahill
Chief Executive Officer and Director
Michelle Lee
President
Email: info@mossgenomics.com
Telephone: 604-629-5974
TikTok: GutHealthTok | Instagram: MossGenomics | LinkedIn: MossGenomics
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Information
This news release includes certain “forward-looking statements” under applicable Canadian securities legislation, including with respect to anticipated product offerings and the objectives and development of the Company. Forward-looking statements are necessarily based upon several estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political, and social uncertainties, and uncertain capital markets. Readers are cautioned that actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/156454
